Core Insights - DBV Technologies reported its financial results for the full year 2025, focusing on advancing its clinical development programs and preparing for the commercialization of the VIASKIN® Peanut Patch [2][3] Financial Performance - Operating income for 2025 was $5.6 million, an increase from $4.2 million in 2024, attributed to higher eligible activities for the French Research Tax Credit [11] - Research and Development (R&D) expenses rose by $27.3 million in 2025 compared to 2024, reflecting increased investment in clinical programs [12] - Selling, General and Administrative (SG&A) expenses increased by $4.6 million in 2025, primarily due to market research activities and operational enhancements for the VIASKIN® Peanut Patch launch [12] - The net loss for 2025 was $147.0 million, compared to $113.9 million in 2024, with a net loss per share of $1.05 for 2025 [13] - Cash and cash equivalents stood at $194 million as of December 31, 2025, a significant increase from $32.5 million in 2024, with net cash used for operating activities at $121.2 million [14] Operational Highlights - The company advanced its clinical development programs for the VIASKIN® Peanut Patch in peanut-allergic toddlers and children, reporting positive topline results from the Phase 3 VITESSE trial [8][10] - A supplemental safety study, COMFORT Toddlers, was initiated for peanut-allergic toddlers aged 1 to 3 years [8] - The company appointed new executives to strengthen its leadership team in preparation for the potential commercialization of the VIASKIN® Peanut Patch [9] Anticipated Events - The company plans to submit a Biologics License Application (BLA) for children aged 4 to 7 years in the first half of 2026, with a potential for Priority Review [15] - Completion of enrollment for the COMFORT Toddlers safety study is expected, with topline results anticipated [15] - A BLA submission for 1-3 year olds is anticipated in the second half of 2026 under an Accelerated Approval Pathway [15]

Core Viewpoint - DBV Technologies has successfully raised €166.7 million through the full exercise of ABSA and BS Warrants, which will support the launch of the VIASKIN® Peanut patch for children aged 4 to 7 years in the U.S., pending approval [1][11]. Financing Details - The financing involved the issuance of 34,090,004 ABSA Warrants and 71,005,656 BS Warrants, leading to the issuance of 59,657,507 new ordinary shares and up to 124,259,898 pre-funded warrants [1][5]. - The exercise price for the ABSA Warrants was €1.5939, while the BS Warrants had an exercise price of €1.5764 [1][6]. Use of Proceeds - The gross proceeds from the exercise will be utilized for working capital, general corporate purposes, and to finance the preparation and submission of a potential Biologics License Application (BLA) for the VIASKIN® Peanut patch [10][11]. - The total financing, including potential exercises of outstanding warrants, is estimated to reach approximately €284.5 million [10]. Shareholder Impact - The issuance of new shares will dilute existing shareholders' equity, with ownership interest for a shareholder holding 1.00% of the Company's share capital decreasing to 0.78% on a non-diluted basis after the issuance [15]. - The shareholding structure will change post-issuance, with Baker Brothers Investments retaining 8.64% and Janus Henderson acquiring 7.54% of the diluted share capital [17]. Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology [19]. - The company is headquartered in Châtillon, France, with operations in North America [20].

Core Insights - DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting from November 6 to 10 in Orlando, Florida [1] - The company will host a Product Theater discussing the benefits of early intervention in food allergy management [2][3] - A planned Phase 2 clinical study will assess the efficacy and safety of the VIASKIN® Peanut patch for peanut-allergic infants aged 6 to 12 months [2][4] Product Theater Details - Dr. Gideon Lack will lead discussions on proactive food allergy management and the potential of the VIASKIN® Peanut patch [3] - The study aims to determine if earlier intervention can facilitate ad lib peanut consumption in young children [3] - Dr. Matthew Greenhawt will present end-of-study results from the EPITOPE study during the meeting [3][8] Company Commitment - DBV Technologies emphasizes its commitment to the younger patient population in the food allergy community [4] - The company anticipates a potential BLA filing for the VIASKIN® Peanut patch for toddlers aged 1 to 3 years in the second half of next year [4] - DBV is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology [9] Event Participation - DBV will exhibit at booth 711 and sponsor the 34th Annual FIT Bowl™, a competition testing knowledge in allergy, asthma, and immunology [6] - The competition is scheduled for November 8, 2025 [6] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [10] - The company is dedicated to transforming the care of individuals with food allergies through innovative therapies [9]